Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: A new target for osteogenesis imperfecta pharmacological therapy

Stem Cells

Volumn 30, Issue 7, 2012, Pages 1465-1476

  Gioia, Roberta ^a   Panaroni, Cristina ^a,b   Besio, Roberta ^a   Palladini, Giovanni ^a,c   Merlini, Giampaolo ^a,c   Giansanti, Vincenzo ^d   Scovassi, Ivana A ^d   Villani, Simona ^a   Villa, Isabella ^e   Villa, Anna ^b,f   Vezzoni, Paolo ^b,f   Tenni, Ruggero ^a   Rossi, Antonio ^a   Marini, Joan C ^g   Forlino, Antonella ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b Milan Unit   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d CNR   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Adipogenesis; Adult stem cell; Adult stem cells differentiation; Autophagy; Osteoblastogenesis; Osteogenesis imperfecta

Indexed keywords

ALPHA5 INTEGRIN; ATAXIN 1; BORTEZOMIB; ENDOGLIN; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; BONE DEVELOPMENT; CELL COUNT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SIZE; COLONY FORMING UNIT F; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; FEMALE; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOGENESIS IMPERFECTA; PROTEIN EXPRESSION; UPREGULATION;

MURINAE; MUS;

EID: 84862906036     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1107     Document Type: Article

References (56)

1. Forlino A, Cabral WA, Barnes AM et al. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol 2011;7:540-557.
2. Marini JC, Forlino A, Cabral WA et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: Regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat 2007;28:209-221.
3. Forlino A, Porter FD, Lee EJ et al. Use of the Cre/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an alpha1(I) G349C substitution. Variability in phenotype in BrtlIV Mice. J Biol Chem 1999;274:37923-37931. (Pubitemid 30026860)
4. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979;16:101-116. (Pubitemid 9164903)
5. Kozloff KM, Carden A, Bergwitz C et al. Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptations to improve whole bone strength. J Bone Miner Res 2004;19:614-622. (Pubitemid 41071222)
6. Uveges TE, Collin-Osdoby P, Cabral WA et al. Cellular mechanism of decreased bone in Brtl mouse model of OI: Imbalance of decreased osteoblast function and increased osteoclasts and their precursors. J Bone Miner Res 2008;23:1983-1994.
7. Forlino A, Tani C, Rossi A et al. Differential expression of both extracellular and intracellular proteins is involved in the lethal or non-lethal phenotypic variation of BrtlIV, a murine model for osteogenesis imperfecta. Proteomics 2007;7:1877-1891. (Pubitemid 46911006)
8. Bellantuono I, Aldahmash A, Kassem M. Aging of marrow stromal (skeletal) stem cells and their contribution to age-related bone loss. Biochim Biophys Acta 2009;1792:364-370.
9. Gimble JM, Zvonic S, Floyd ZE et al. Playing with bone and fat. J Cell Biochem 2006;98:251-266.
10. Taipaleenmaki H, Abdallah BM, AlDahmash A et al. Wnt signalling mediates the cross-talk between bone marrow derived pre-adipocytic and pre-osteoblastic cell populations. Exp Cell Res 2011;317: 745-756.
11. Mendez-Ferrer S, Michurina TV, Ferraro F et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010;466:829-834.
12. Post S, Abdallah BM, Bentzon JF et al. Demonstration of the presence of independent pre-osteoblastic and pre-adipocytic cell populations in bone marrow-derived mesenchymal stem cells. Bone 2008;43:32-39.
13. Tornvig L, Mosekilde LI, Justesen J et al. Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif Tissue Int 2001;69:46-50. (Pubitemid 32702265)
14. Harslof T, Wamberg L, Moller L et al. Rosiglitazone decreases bone mass and bone marrow fat. J Clin Endocrinol Metab 2011;96: 1541-1548.
15. Xu Y, Shi Y, Ding S. A chemical approach to stem-cell biology and regenerative medicine. Nature 2008;453:338-344. (Pubitemid 351693140)
16. Chen D, Frezza M, Schmitt S et al. Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives. Curr Cancer Drug Targets 2011;11:239-253.
17. Mukherjee S, Raje N, Schoonmaker JA et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 2008;118:491-504. (Pubitemid 351206540)
18. Uveges TE, Kozloff KM, Ty JM et al. Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation. J Bone Miner Res 2009;24:849-859.
19. Panaroni C, Gioia R, Lupi A et al. In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta. Blood 2009;114:459-468.
20. Vanky P, Brockstedt U, Hjerpe A et al. Kinetic studies on epiphyseal growth cartilage in the normal mouse. Bone 1998;22:331-339. (Pubitemid 28177185)
21. Evans KD, Lau ST, Oberbauer AM et al. Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta. Bone 2003;32:268-274. (Pubitemid 36349530)
22. Sun S, Guo Z, Xiao X et al. Isolation of mouse marrow mesenchymal progenitors by a novel and reliable method. Stem Cells 2003;21: 527-535. (Pubitemid 37444109)
23. Anjos-Afonso F, Siapati EK, Bonnet D. In vivo contribution of murine mesenchymal stem cells into multiple cell-types under minimal damage conditions. J Cell Sci 2004;117:5655-5664. (Pubitemid 40012211)
24. Quarto N, Longaker MT. FGF-2 inhibits osteogenesis in mouse adipose tissue-derived stromal cells and sustains their proliferative and osteogenic potential state. Tissue Eng 2006;12:1405-1418. (Pubitemid 44174777)
25. Meirelles Lda S, Nardi NB. Murine marrow-derived mesenchymal stem cell: Isolation, in vitro expansion, and characterization. Br J Haematol 2003;123:702-711. (Pubitemid 37468069)
26. Krings A, Rahman S, Huang S et al. Bone marrow fat has brown adipose tissue characteristics, which are attenuated with aging and diabetes. Bone 2012;50:546-552.
27. Forlino A, Kuznetsova NV, Marini JC et al. Selective retention and degradation of molecules with a single mutant alpha1(I) chain in the Brtl IV mouse model of OI. Matrix Biol 2007;26:604-614. (Pubitemid 350180392)
28. Ishida Y, Yamamoto A, Kitamura A et al. Autophagic elimination of misfolded procollagen aggregates in the endoplasmic reticulum as a means of cell protection. Mol Biol Cell 2009;20:2744-2754.
29. Baerga R, Zhang Y, Chen PH et al. Targeted deletion of autophagy-related 5 (atg5) impairs adipogenesis in a cellular model and in mice. Autophagy 2009;5:1118-1130.
30. Zhang Y, Goldman S, Baerga R et al. Adipose-specific deletion of autophagy-related gene 7 (atg7) in mice reveals a role in adipogenesis. Proc Natl Acad Sci USA 2009;106:19860-19865.
31. Ishida Y, Nagata K. Hsp47 as a collagen-specific molecular chaperone. Methods Enzymol 2011;499:167-182.
32. Kassem M, Abdallah BM, Saeed H. Osteoblastic cells: Differentiation and trans-differentiation. Arch Biochem Biophys 2008;473:183-187.
33. Abdallah BM, Kassem M. New factors controlling the balance between osteoblastogenesis and adipogenesis. Bone 2012;50:540-545.
34. Savopoulos C, Dokos C, Kaiafa G et al. Adipogenesis and osteoblastogenesis: Trans-differentiation in the pathophysiology of bone disorders. Hippokratia 2011;15:18-21.
35. Crossno JT, Jr., Majka SM, Grazia T et al. Rosiglitazone promotes development of a novel adipocyte population from bone marrow-derived circulating progenitor cells. J Clin Invest 2006;116:3220-3228. (Pubitemid 44878636)
36. Hausman GJ, Hausman DB. Search for the preadipocyte progenitor cell. J Clin Invest 2006;116:3103-3106. (Pubitemid 44878622)
37. Cecconi F, Levine B. The role of autophagy in mammalian development: Cell makeover rather than cell death. Dev Cell 2008;15: 344-357.
38. Kilian KA, Bugarija B, Lahn BT et al. Geometric cues for directing the differentiation of mesenchymal stem cells. Proc Natl Acad Sci USA 2010;107:4872-4877.
39. Bamber BA, Rowland AM. Shaping cellular form and function by autophagy. Autophagy 2006;2:247-249. (Pubitemid 44030898)
40. Singh R, Xiang Y, Wang Y et al. Autophagy regulates adipose mass and differentiation in mice. J Clin Invest 2009;119:3329-3339.
41. Chen XD, Shi S, Xu T et al. Age-related osteoporosis in biglycan-deficient mice is related to defects in bone marrow stromal cells. J Bone Miner Res 2002;17:331-340. (Pubitemid 34087666)
42. Bi Y, Stuelten CH, Kilts T et al. Extracellular matrix proteoglycans control the fate of bone marrow stromal cells. J Biol Chem 2005;280: 30481-30489. (Pubitemid 41216232)
43. Genin E, Reboud-Ravaux M, Vidal J. Proteasome inhibitors: Recent advances and new perspectives in medicinal chemistry. Curr Top Med Chem 2010;10:232-256.
44. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004;5:417-421. (Pubitemid 38610244)
45. Zangari M, Terpos E, Zhan F et al. Impact of bortezomib on bone health in myeloma: A review of current evidence. Cancer Treat Rev 2012. DOI: 10.1016/j.ctvr.2011.12.007.
46. Zangari M, Yaccoby S, Pappas L et al. A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica 2011;96:333-336.
47. Terpos E, Christoulas D, Kokkoris P et al. Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. Ann Oncol 2010;21:1561-1562.
48. Heider U, Kaiser M, Mieth M et al. Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur J Haematol 2009;82:31-38.
49. Terpos E, Christoulas D, Katodritou E et al. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy. Int J Cancer 2011;2011:27342. DOI: 10.1002/ijc27342.
50. Ozaki S, Tanaka O, Fujii S et al. Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma. Int J Hematol 2007;86:180-185. (Pubitemid 47425199)
51. Kim M, Nakamoto T, Nishimori S et al. A new ubiquitin ligase involved in p57KIP2 proteolysis regulates osteoblast cell differentiation. EMBO Rep 2008;9:878-884.
52. Giuliani N, Morandi F, Tagliaferri S et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007;110:334-338. (Pubitemid 47026851)
53. Sanguinetti C, Greco F, De Palma L et al. Morphological changes in growth-plate cartilage in osteogenesis imperfecta. J Bone Joint Surg Br 1990;72:475-479. (Pubitemid 20154165)
54. Horwitz EM, Prockop DJ, Gordon PL et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001;97:1227-1231. (Pubitemid 32183743)
55. Horwitz EM, Gordon PL, Koo WK et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 2002;99:8932-8937. (Pubitemid 34693661)
56. Vanleene M, Saldanha Z, Cloyd KL et al. Transplantation of human fetal blood stem cells in the osteogenesis imperfecta mouse leads to improvement in multiscale tissue properties. Blood 2011;117:1053-1060.